Form 4: ADMA Biologics CEO Adam Grossman Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Adam Grossman, CEO of ADMA Biologics, reports the disposal of shares to cover tax obligations related to vesting restricted stock units (RSUs).
Summary
- On March 6 and 7, 2024, Adam Grossman, the President and CEO of ADMA Biologics, disposed of shares of common stock to satisfy tax obligations related to the vesting of Restricted Stock Units (RSUs).
- On March 6, 2024, 55,003 shares were disposed of at a price of $6.12.
- On March 7, 2024, 28,763 shares were disposed of at a price of $6.16.
- Following these transactions, Grossman directly owns 2,673,227 shares of common stock.
- Grossman also indirectly owns 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions for tax purposes, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the small number of shares disposed of by the CEO.
Key Dates
| Date | Description |
|---|---|
| 03/06/2024 | Disposal of 55,003 shares of common stock at $6.12. |
| 03/07/2024 | Disposal of 28,763 shares of common stock at $6.16. |
| 03/08/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.